Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Hutchmed cancer treatment indication accepted for review in China
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA). The AIM-traded firm said the application was targeting adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) featuring mesenchymal epithelial transition factor (MET) exon 14 skipping alteration.
If approved, the application would expand the label indication for savolitinib to include treatment-naive patients in China.
Savolitinib, previously granted conditional approval in China for treating NSCLC patients with MET exon 14 skipping alterations who had progressed following prior systemic therapy or who were ineligible for chemotherapy, had been marketed under the brand name 'Orpathys' by Hutchmed's partner AstraZeneca.
That, the board sid, represented a groundbreaking development as the first selective MET inhibitor approved in China.
Given that a significant portion of lung cancer patients globally, and particularly in China, exhibited NSCLC with MET exon 14 skipping alterations, the expansion of savolitinib's indication held considerable promise for addressing an unmet medical need.
The acceptance of the sNDA followed the presentation of preliminary efficacy and safety data from the first-line cohort of the confirmatory phase 3b clinical trial at the IASLC World Conference on Lung Cancer in September.
Subsequently, the final data from the trial were presented at the European Lung Cancer Congress on 20 March.
Noteworthy outcomes from the phase 3b trial included an objective response rate (ORR) of 62.1% and 39.2% in treatment-naïve and previously-treated patients, respectively, along with favourable disease control rates and median durations of response.
Moreover, the safety profile of savolitinib was found to be tolerable, with no new safety signals observed.
The global licensing and collaboration agreement between AstraZeneca and Hutchmed, initiated in 2011, sees Hutchmed spearheading the drug's development in China, while AstraZeneca leads development efforts outside of China with responsibility for commercialisation worldwide.
At 1203 GMT, Hutchmed China shares were down 1.13% at 261.51p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.